| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2022-07-19 |
| タイトル |
|
|
タイトル |
Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
Idiopathic pulmonary fibrosis |
| キーワード |
|
|
主題 |
lung cancer |
| キーワード |
|
|
主題 |
antifibrotic therapy |
| キーワード |
|
|
主題 |
incidence |
| キーワード |
|
|
主題 |
prevalence |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| その他のタイトル |
|
|
その他のタイトル |
Impact of antifibrotic therapy on lung cancer development in IPF |
| 著者 |
Naoi, Hyogo
Suzuki, Yuzo
Mori, Kazutaka
Aono, Yuya
Kono, Masato
Hasegawa, Hirotsugu
Yokomura, Koshi
Inoue, Yusuke
Hozumi, Hironao
Karayama, Masato
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Inui, Naoki
Nakamura, Hidenori
Suda, Takafumi
|
| 書誌情報 |
Thorax
巻 77,
号 7,
p. 727-730,
発行日 2022
|
| 出版者 |
|
|
出版者 |
BMJ Publishing Group |
| 権利 |
|
|
権利情報 |
"This article has been accepted for publication in ""Thorax, 2022"" following peer review, and the Version of Record can be accessed online at ""http://dx.doi.org/10.1136/thoraxjnl-2021-218281""." |
| 権利 |
|
|
権利情報 |
?Authors (or their employer(s)) 2022: “Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) http://creativecommons.org https://creativecommons.org/licenses/by-nc/4.0/” |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk for lung cancer (LC). Antifibrotic therapy slows disease progression and possibly prolongs survival. However, whether antifibrotic therapy affects LC-development in IPF patients remains unknown. This multi-centre retrospective study evaluated 345 IPF patients. The incidence and prevalence of LC were significantly lower in IPF patients receiving antifibrotic therapy than those not. Subsequently, LC-related mortality was significantly lower in IPF patients receiving antifibrotic therapy. These results suggest that antifibrotic therapy was possibly associated with a reduced risk of LC-development in IPF patients, which may be partly associated with its survival benefit. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0040-6376 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1468-3296 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
35354649 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1136/thoraxjnl-2021-218281 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
Thorax-77-727.pdf (305.2 kB)
.png)
